The prescription weight control medicine lorcaserin (Belviq, Belviq XR) may increase the risk for cancer, according to the results of a clinical trial assessing the safety of the drug, the U.S. Food and Drug Administration says. The agency said, “[W]e cannot conclude that lorcaserin contributes to the cancer risk” but “wanted to make the public...